关键词: 胃肠间质瘤, 甲磺酸伊马替尼, 血药浓度

Abstract:

Therapeutic drug monitoring of plasma imatinib mesylate for the treatment of gastrointestinal stromal tumor and prognosis        XU Ze-kuan, XU Hao. Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
Corresponding author: XU Ze-kuan, E-mail:xuzekuan@njmu.edu.cn
Abstract    Imatinib mesylate is a tyrosine kinase inhibitor recommended for treatment in patients with unresectable，metastastic and relapsing GIST as well as patients who have been identified with moderate or high risk of recurrence after receiving complete tumor resection. Imatinib plasma trough concentration（Cmin） is significantly correlated with better clinical benefit when Cmin >1100μg/L. Therapeutic drug monitoring (TDM) for plasma imatinib is becoming a potential adjuvant therapy for GIST.

Key words: gastrointestinal stromal tumor, imatinib mesylate, plasma concentration